Cargando…

Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem

Based on compelling preclinical evidence concerning the progress of our novel ruthenium-based metallotherapeutics, we are focusing research efforts on challenging indications for the treatment of invasive neoplasms such as the triple-negative breast cancer (TNBC). This malignancy mainly afflicts you...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferraro, Maria Grazia, Bocchetti, Marco, Riccardi, Claudia, Trifuoggi, Marco, Paduano, Luigi, Montesarchio, Daniela, Misso, Gabriella, Santamaria, Rita, Piccolo, Marialuisa, Irace, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094725/
https://www.ncbi.nlm.nih.gov/pubmed/37047448
http://dx.doi.org/10.3390/ijms24076473
_version_ 1785023910358548480
author Ferraro, Maria Grazia
Bocchetti, Marco
Riccardi, Claudia
Trifuoggi, Marco
Paduano, Luigi
Montesarchio, Daniela
Misso, Gabriella
Santamaria, Rita
Piccolo, Marialuisa
Irace, Carlo
author_facet Ferraro, Maria Grazia
Bocchetti, Marco
Riccardi, Claudia
Trifuoggi, Marco
Paduano, Luigi
Montesarchio, Daniela
Misso, Gabriella
Santamaria, Rita
Piccolo, Marialuisa
Irace, Carlo
author_sort Ferraro, Maria Grazia
collection PubMed
description Based on compelling preclinical evidence concerning the progress of our novel ruthenium-based metallotherapeutics, we are focusing research efforts on challenging indications for the treatment of invasive neoplasms such as the triple-negative breast cancer (TNBC). This malignancy mainly afflicts younger women, who are black, or who have a BRCA1 mutation. Because of faster growing and spreading, TNBC differs from other invasive breast cancers having fewer treatment options and worse prognosis, where existing therapies are mostly ineffective, resulting in a large unmet biomedical need. In this context, we benefited from an experimental model of TNBC both in vitro and in vivo to explore the effects of a biocompatible cationic liposomal nanoformulation, named HoThyRu/DOTAP, able to effectively deliver the antiproliferative ruthenium(III) complex AziRu, thus resulting in a prospective candidate drug. As part of the multitargeting mechanisms featuring metal-based therapeutics other than platinum-containing agents, we herein validate the potential of HoThyRu/DOTAP liposomes to act as a multimodal anticancer agent through inhibition of TNBC cell growth and proliferation, as well as migration and invasion. The here-obtained preclinical findings suggest a potential targeting of the complex pathways network controlling invasive and migratory cancer phenotypes. Overall, in the field of alternative chemotherapy to platinum-based drugs, these outcomes suggest prospective brand-new settings for the nanostructured AziRu complex to get promising goals for the treatment of metastatic TNBC.
format Online
Article
Text
id pubmed-10094725
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100947252023-04-13 Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem Ferraro, Maria Grazia Bocchetti, Marco Riccardi, Claudia Trifuoggi, Marco Paduano, Luigi Montesarchio, Daniela Misso, Gabriella Santamaria, Rita Piccolo, Marialuisa Irace, Carlo Int J Mol Sci Article Based on compelling preclinical evidence concerning the progress of our novel ruthenium-based metallotherapeutics, we are focusing research efforts on challenging indications for the treatment of invasive neoplasms such as the triple-negative breast cancer (TNBC). This malignancy mainly afflicts younger women, who are black, or who have a BRCA1 mutation. Because of faster growing and spreading, TNBC differs from other invasive breast cancers having fewer treatment options and worse prognosis, where existing therapies are mostly ineffective, resulting in a large unmet biomedical need. In this context, we benefited from an experimental model of TNBC both in vitro and in vivo to explore the effects of a biocompatible cationic liposomal nanoformulation, named HoThyRu/DOTAP, able to effectively deliver the antiproliferative ruthenium(III) complex AziRu, thus resulting in a prospective candidate drug. As part of the multitargeting mechanisms featuring metal-based therapeutics other than platinum-containing agents, we herein validate the potential of HoThyRu/DOTAP liposomes to act as a multimodal anticancer agent through inhibition of TNBC cell growth and proliferation, as well as migration and invasion. The here-obtained preclinical findings suggest a potential targeting of the complex pathways network controlling invasive and migratory cancer phenotypes. Overall, in the field of alternative chemotherapy to platinum-based drugs, these outcomes suggest prospective brand-new settings for the nanostructured AziRu complex to get promising goals for the treatment of metastatic TNBC. MDPI 2023-03-30 /pmc/articles/PMC10094725/ /pubmed/37047448 http://dx.doi.org/10.3390/ijms24076473 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ferraro, Maria Grazia
Bocchetti, Marco
Riccardi, Claudia
Trifuoggi, Marco
Paduano, Luigi
Montesarchio, Daniela
Misso, Gabriella
Santamaria, Rita
Piccolo, Marialuisa
Irace, Carlo
Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem
title Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem
title_full Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem
title_fullStr Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem
title_full_unstemmed Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem
title_short Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem
title_sort triple negative breast cancer preclinical therapeutic management by a cationic ruthenium-based nucleolipid nanosystem
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094725/
https://www.ncbi.nlm.nih.gov/pubmed/37047448
http://dx.doi.org/10.3390/ijms24076473
work_keys_str_mv AT ferraromariagrazia triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem
AT bocchettimarco triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem
AT riccardiclaudia triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem
AT trifuoggimarco triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem
AT paduanoluigi triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem
AT montesarchiodaniela triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem
AT missogabriella triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem
AT santamariarita triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem
AT piccolomarialuisa triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem
AT iracecarlo triplenegativebreastcancerpreclinicaltherapeuticmanagementbyacationicrutheniumbasednucleolipidnanosystem